Blog

Novartis to Buy AveXis in $8.7 Billion US Gene-Therapy Deal – Bloomberg

Novartis to Buy AveXis in $8.7 Billion US GeneTherapy Deal
Bloomberg
Novartis AG agreed to acquire AveXis Inc. for $8.7 billion to expand its position in gene therapy. Switzerland-based Novartis is buying the Bannockburn, Illinois, company for $218 a share, representing a premium of 88 percent to AveXis's closing price

2018-04-09 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.